A scientist comments on the evolving treatment of rectal cancer in light of findings from a study that found the immunotherapy drug dostarlimab was especially effective in a phase II clinical trial of a dozen patients with a subtype of rectal cancer. https://www.sciencedaily.com/releases/2022/06/220605130358.htm
